Vyvanse is a prescription medicine used for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients 6 years and above, and for the treatment of moderate to severe binge eating disorder (B.E.D.) in adults. Vyvanse is not for weight loss. It is not known if Vyvanse is safe and effective for the treatment of obesity.

Important Safety Information

Vyvanse is a federally controlled substance (CII) because it can be abused or lead to dependence. Keep Vyvanse in a safe place to prevent misuse and abuse. Selling or giving away Vyvanse may harm others and is against the law. Safety information continued below Safety Information Continued Below

Contact us

Patients and Caregivers

If you would like additional information or need to report an adverse event, please contact the Shire Customer Service Center in the US at 1-800-828-2088, M–F 8:30 AM to 5:00 PM ET.

Health Care Professionals

Clinical inquiries: For further clinical information on Shire products, US doctors may call tollā€free at 1-800-828-2088, or send an e-mail to medinfoglobal@shire.com.

Shire US Inc.
300 Shire Way
Lexington, MA 02421 

Sponsored By


Please be advised that Shire Pharmaceuticals has no control over the content or presentation of the site you are about to view.

back continue


Please be advised that you are now leaving this site and about to enter the Vitals website where you can use the Vitals physician finder service to locate a physician who treats ADHD. You are encouraged to review the privacy and terms of use policies governing the website.

Linking to the Vitals website is provided as a resource to our visitors and does not imply an endorsement or recommendation of a particular physician by Shire Pharmaceuticals, nor an endorsement of any Shire product by any physician located using the Vitals physician finder. All prescription decisions are at the sole discretion of the physician. Shire Pharmaceuticals accepts no responsibility or liability for the content of or the services provided via the Vitals website.

back continue

You are about to leave this site

You are being directed to another website.

back continue